Indivior Share Discussion Threads

[la forge] 26/2/2020 11:48

jayminpatel1
26 Feb '20 - 11:43 - 2438 of 2439
0 0 0
Indivior Sinks As It Warns Of 2020 Loss And Potential Legal Costs


BEHIND THE TIMES

SEEMS OLD NEWS

2 WEEKS OLD APPROX

[la forge] 26/2/2020 11:46

Price (GBX) 39.95 Var % (+/-) +3.10% (Up +1.20)
High 39.95 Low 38.25
Volume 952,430 Last close 38.75 on 25-Feb-2020
Bid 39.93 Offer 40.12
Trading status Regular Trading Special conditions NONE

[jayminpatel1] 26/2/2020 11:43

Indivior Sinks As It Warns Of 2020 Loss And Potential Legal Costs

[la forge] 25/2/2020 09:25

Citigroup Neutral down from 58.00 to 45.00 Reiterates

[ohno1] 22/2/2020 18:46

nicelilyishere filtered

[ali47fish] 22/2/2020 16:27

nicelilyhere - not nice filtered

[misca2] 22/2/2020 15:05

nicelilyishere
22 Feb '20 - 15:01 - 2433 of 2433 (Filtered)


0 0 0

[misca2] 22/2/2020 15:00

Opioid settlement still elusive as some lawyers criticize it
Feb. 22, 2020 at 5:10 am Updated Feb. 22, 2020 at 6:49 am
FILE – In this Nov. 1, 2018, file photo, Patrick Morrisey speaks to reporters after a debate in Morgantown, W.Va. State attorneys general are finding a national settlement over the toll of opioids to be elusive, as some lawyers for state and local governments are renewing public criticism of the proposed deal with a group of companies led by the nation’s largest drug distributors. In a statement Friday, Feb. 21, 2020, Morrisey, the attorney general in West Virginia, one of the states hit hardest by the opioid crisis, said the $22 billion in cash being offered by distributors AmerisourceBergen, Cardinal Health and McKesson plus drugmaker Johnson & Johnson “is way too low.”(AP Photo/Raymond Thompson, File)
FILE – In this Nov. 1, 2018, file photo, Patrick Morrisey speaks to reporters after a debate in Morgantown, W.Va. State attorneys general are... (AP Photo/Raymond Thompson, File) More
By GEOFF MULVIHILL
The Associated Press

State attorneys general are finding a national settlement over the toll of opioids to be elusive, as some lawyers for state and local governments are renewing public criticism of the proposed deal with a group of companies led by the nation’s largest drug distributors.

A group of top state lawyers in October announced the framework for a deal that they said would be worth about $48 billion in cash, treatment drugs and services over time.

Some state attorneys general and lawyers for local governments criticized it at the time. They’re speaking up anew as the push continues to reach a deal, with a trial over opioids scheduled to start next month in New York .

In a statement Friday, Patrick Morrisey, the attorney general in West Virginia, one of the states hit hardest by the opioid crisis, said the $22 billion in cash being offered by distributors AmerisourceBergen, Cardinal Health and McKesson plus drugmaker Johnson & Johnson “is way too low.”

Under terms previously announced, Teva Pharmaceuticals would also provide a free addiction treatment drug, and the other companies would distribute it.

Morrisey also said that the money would not be allocated fairly under the plan as it stood because states’ shares would be based too much on population and not enough on the impact of the crisis.

Advertising

“When addressing a national public health crisis, a global settlement shouldn’t be about a pure money grab for the states,” he said. “Monies should be targeted to those who need it most and spent on abatement.”

His statement showed that at least some attorneys general remain resolute not to accept the offer a week after 21 of them signed a letter saying they opposed the deal as offered.

Lead lawyers for more than 2,500 local governments suing the drug industry said Friday that the companies have offered an additional $1.2 billion in cash over 18 years. The lawyers said that’s not enough: “Concerns remain that the total value being proposed is not adequate nor does it provide any degree of assurance that resources will reach communities.”

The attorneys general from North Carolina, Pennsylvania, Tennessee and Texas who championed the settlement in October said it was better to have a national deal than see money go out piecemeal — while it lasts — through trial judgments.

Prescription and illicit painkillers have been linked to more than 430,000 deaths in the U.S. in the past two decades, and they’ve created financial burdens for families who have lost incomes and governments who have seen public service expenses rise as they’ve tried to deal with the crisis.

The offices of several attorneys general who have supported the deal have declined comment or not returned messages.

The companies also did not respond to messages or did not comment on Friday night.

Earlier in the week, McKesson said in a statement that it was trying to finalize a settlement settlement “that would serve as the best path forward to provide billions of dollars in immediate funding and relief to states and local communities.”

___

Follow Mulvihill at

GEOFF MULVIHILL

[grupo] 22/2/2020 08:38

Price (GBX) 37.50 Var % (+/-) +6.96% (Up +2.44)

High 37.74 Low 34.47

Volume 2,100,828 Last close 37.50 on 21-Feb-2020

Bid 37.50 Offer 37.81

Trading status Market Close Special conditions NONE

[gibbs1] 20/2/2020 14:30

Feb 20, 2020

Financial Arrangements Made

[waldron] 19/2/2020 17:30

Price (GBX) 36.00 Var % (+/-) -1.85% (Down -0.68)
High 37.67 Low 35.18
Volume 1,682,280 Last close 36.00 on 19-Feb-2020
Bid 35.79 Offer 36.20
Trading status Post-Close Special conditions NONE

[waldron] 19/2/2020 15:24

STRONG SUPPORT AT 34p

[waldron] 17/2/2020 16:55

Price (GBX) 40.00 Var % (+/-) +0.73% (Up +0.29)
High 41.10 Low 39.62
Volume 1,929,000 Last close 40.00 on 17-Feb-2020
Bid 39.91 Offer 40.11
Trading status Closing Price Crossing Special conditions NONE

[timmy11] 14/2/2020 23:00

1leetrader what does it say ?

[gibbs1] 14/2/2020 21:09

misca2
14 Feb '20 - 18:30 - 2422 of 2422
0 1 0
1leetrader
14 Feb '20 - 17:00 - 2421 of 2421 (Filtered)


0 0 2

DONE

[misca2] 14/2/2020 18:30

1leetrader
14 Feb '20 - 17:00 - 2421 of 2421 (Filtered)


0 0 2

[waldron] 14/2/2020 16:52

Price (GBX) 39.71 Var % (+/-) +0.35% (Up +0.14)
High 40.51 Low 37.18
Volume 3,241,449 Last close 39.71 on 14-Feb-2020
Bid 40.00 Offer 40.01
Trading status Closing Price Crossing Special conditions NONE

[waldron] 14/2/2020 16:13

Drugs and the law: Can Indivior recover again after 38% dive?
by Graeme Evans from interactive investor | 13th February 2020 15:11

Another stock that’s staged a strong recovery only to disappoint shareholders again.


Having lost two-thirds of its value in 2019, pharmaceuticals stock Indivior (LSE:INDV) remains gripped by legal and trading uncertainties after warning it expects to rack up a full-year loss in 2020.

Shares in the company, whose best-selling opioid addiction drug Suboxone Film is under pressure from recently-launched copycat versions, are now back where they were at the end of 2019 following today's slide of 25% to 36p in the wake of Q4 and full-year results.

Slough-based Indivior was London's seventh-worst performing mid-cap stock of 2019, with its 65% decline only “bettered̶1; by the likes of Metro Bank (LSE:MTRO), Sirius Minerals (LSE:SXX) and Ted Baker (LSE:TED).

The stock fell to as low as 30p last April after the company was indicted in the United States over an "illicit nationwide scheme" to drive prescriptions of Suboxone.

Source: TradingView Past performance is not a guide to future performance

Indivior continues to fight the allegations, which stem from a federal investigation launched in 2013 and before the company was demerged from household goods giant Reckitt Benckiser in 2014. As the Department of Justice is seeking to recover US$3 billion, the case continues to be a major source of worry for the company and its shareholders.

CEO Shaun Thaxter said the business was proactively looking to manage these risks, adding: “Although we are optimistic about delivering on our strategic priorities in 2020, we of course recognise the legal uncertainties we face.”

He forecast a further drop in sales this year, with net revenues set to be in the range of $525 million and $585 million. They declined 22% to $785 million in today's full-year results following the loss of market share for Suboxone Film to generic competitors.

The figure was still more than $200 million higher than forecast earlier this year after a US court allowed Indian firm Dr Reddy's and Alvogen to launch rival versions from February 2019.

In 2018, Indivior boasted a Suboxone market share in the US of around 53%, representing some 80% of the $1 billion in revenues generated at the time. This eroded to 24% by the end of the 2019 financial year, although the rate of decline has been slower than expected.

The impact has been partly offset by the transition towards Indivior's newer injectable treatment Sublocade, which generated revenues of $72 million in 2019 and is expected to reach between $150 million and $200 million this year. Indivior believes Sublocade has the potential to become a “sustainable $1 billion franchise”.

Despite this growth, Indivior expects to post losses for this year of between $20 million and $50 million. The deficit for the fourth quarter of 2019 was $55 million, leading to a 51% decline in net income for the year to $134 million.

These articles are provided for information purposes only.

[maywillow] 14/2/2020 13:06

FILS PREVIOUSLY HELD 4.71pc

[maywillow] 14/2/2020 11:34

Indivior shares are ‘attractive217;, says Numis

Indivior (INDV), maker of addiction treatment drugs, may have reported a £42m loss in the fourth quarter but Numis believes the shares are ‘highly attractive’.

Analyst Paul Cuddon retained his ‘buy’ recommendation and target price of 160p on the stock, which tumbled 19.6% to 39.6p yesterday.

‘Indivior continues to lead the battle against the opioid epidemic and has delivered $785m in sales, in line with our expectations and toward the upper end of guidance, which had been upgraded twice during the year,’ he said.

‘The company has also ramped up sales and marketing investment, which has aided performance of [opioid addiction treatment] Sublocade, and sets the product for continued strong growth into full-year 2020. We continue to find the risk-reward highly attractive.’